|本期目录/Table of Contents|

[1]任成山,卞士柱,胡明冬.肺动脉高压的成因及治疗新理念[J].中华肺部疾病杂志,2023,(01):1-5.[doi:10.3877/cma.j.issn.1674-6902.2023.01.001 ]
点击复制

肺动脉高压的成因及治疗新理念(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2023年01期
页码:
1-5
栏目:
专家论坛
出版日期:
2023-02-20

文章信息/Info

Title:
-
作者:
任成山1; 2; 卞士柱3; 胡明冬4
《中华肺部疾病杂志(电子版)》编辑部1 400037 重庆,陆军(第三)军医大学第二附属医院消化内科2、心血管内科CCU3、老年医学与特勤医学科4
Author(s):
-
关键词:
肺动脉高压;  肺动脉平滑肌细胞;  成因/病因;  靶向治疗;  纳米晶体颗粒;  FoxO1;  Caspase 3
Keywords:
-
分类号:
R563
DOI:
10.3877/cma.j.issn.1674-6902.2023.01.001
摘要:
-
Abstract:
-

参考文献/References:

1 Jacobs W, van de Veerdonk MC, Trip P, et al. The right ventricle explains sex differences in survival in idiopathic pulmonary arterial hypertension[J]. Chest, 2014, 145: 1230-6. 10.1378/chest.13-1291.
2 Hatton N, Ryan JJ. Sex differences in response to pulmonary arterial hypertension therapy: is what's good for the goose, good for the gander?[J]. Chest, 2014, 145: 1184-6. 10.1378/chest.13-3061
3 Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review[J]. Pulm Circ, 2021, 11: 2045894020977300.
4 中华医学会呼吸病学分会肺栓塞与肺血管病学组 中国医师协会呼吸医师分会 肺栓塞与肺血管病工作委员会 全国肺栓塞与肺血管病防治协作组 全国肺动脉高压标准化体系建设项目专家组. 中国肺动脉高压诊断与治疗指南(2021版)[J]. 中华医学杂志, 2021, 101(1): 11-51.
5 Marc Humbert, Gabor Kovacs, Marius M Hoeper, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Heart J, 2022, 43(38): 3618-3731.
6 Fu C, Hao S, Liu Z, et al. SOD2 ameliorates pulmonary hypertension in a murine model of sleep apnea via suppressing expression of NLRP3 in CD11b+cells[J]. Respir Res, 2020, 21(1): 9.
7 Jia H, Liu Y, Guo D, et al. PM2.5-induced pulmonary inflammation via activating of the NLRP3/caspase-1 signaling pathway[J]. Environ Toxicol, 2021, 36(3): 298-307.
8 Hoeper MM, Ghofrani HA, Grünig E, et al. Pulmonary hypertension [J]. Dtsch Arztebl Int, 2017, 114(5): 73-84.
9 Li Hu, Jie Wang, Huijie Huang, et al. YTHDF1 regulates pulmonary hypertension through translational control of MAGED1[J]. Am J Respir Crit Care Med, 2021, 203(9): 1158-1172.
10 Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension[J]. Lancet Respir Med, 2016, 4: 306-322.
11 王 艳, 张向峰, 孙 茜, 等. 门脉高压相关性肺动脉高压临床分析[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(1): 28-33.
12 Mandras SA, Mehta HS, Vaidya A. Pulmonary hypertension: A brief guide for clinicians[J]. Mayo Clin Proc, 2020, 95(9): 1978-1988.
13 熊长明, 翟振国, 王 辰. 修改肺动脉高压诊断标准带来的争议及其影响[J]. 中华医学杂志, 2020, 100(22): 1684-1687.
14 Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology(ESC)and the European Respiratory Society(ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology(AEPC), International Society for Heart and Lung Transplantation(ISHLT)[J]. Eur Heart J, 2016, 37: 67-119.
15 Maron BA, Brittain EL, Hess E, et al. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study[J]. Lancet Respir Med, 2020, 8: 873-884.
16 Xanthouli P, Jordan S, Milde N, et al. Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension[J]. Ann Rheum Dis, 2020, 79: 370-378.
17 Pieske B, Tschope C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association(HFA)of the European Society of Cardiology(ESC)[J]. Eur Heart J, 2019, 40: 3297-3317.
18 Zeder K, Banfi C, Steinrisser-Allex G, et al. Diagnostic, prognostic and differential-diagnostic relevance of pulmonary hemodynamics during exercise-a systematic review[J]. Eur Respir J, 2022, doi:10.1183/13993003.03181-2021
19 Semenza GL. HIF-1 mediates the Warburg effect in clear cell renal carcinoma[J]. J Bioenerg Biomembr, 2007, 39: 231-4. 10.1007/s10863-007-9081-2
20 Hafeez N, Chan SY. A New“TYK”tokera for the study of long noncoding RNAs in pulmonary hypertension[J]. Am J Respir Crit Care Med, 2020, 202(10): 1339-1341.
21 Thenappan T, Ormiston ML, Ryan JJ, et al. Pulmonary arterial hypertension: pathogenesis and clinical management[J]. BMJ, 2018, 360: j5492.
22 Liu A, Li B, Yang M. Targeted treprostinil delivery inhibits pulmonary arterial remodeling[J]. Eur J Pharmacol, 2022, 923: 174700.
23 Babicheva A, Zhao T, Yuan JX. KC-NK3 channel: a new new player in the field of painenary vascular disease[J]. Cire Res, 2019, 125(7): 696-698.
24 Li JF, Chen YQ, Wang L, et al. Editorial: Calcium and pulmonary hypertension[J]. Front Physiol, 2022,13: 1019158.
25 Teymouri Rad R, Dadashzadeh S, Vatanara A, et al. Tadalafil nanocomposites as a dry powder formulation for inhalation, a new strategy for pulmonary arterial hypertension treatment[J]. Eur J Pharm Sci, 2019, 133: 275-286.
26 Montani D, Girerd B, Jais X, et al. Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation[J]. Eur Respir J, 2020, 58: 2004229.
27 Morrell NW, Aldred MA, Chung WK, et al. Genetics and genomics of pulmonary arterial hypertension[J]. Eur Respir J,2019, 53: 1801899.
28 Li Y, Ma Z, Jiang S, Hu W, et al. A global perspective on FOXO1 in lipid metabolism and lipid-related diseases[J]. Prog Lipid Res, 2017, 66: 42-49.
29 Humbert M, Ghofrani HA. The molecular targets of approved treatments for pulmonary arterial hypertension[J]. Thorax, 2016, 71(1): 73-83.
30 Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension[J]. Eur Respir J, 2019, 53(1): 1801889.
31 Paulin R, MichelakisED. Addressing complexity in pulmonary hypertension:the FoxO1 case[J]. Circ Res, 2015, 116(11): 1732-1735.
32 Barman SA, Li X, Haigh S, et al. Galectin-3 is expressed in vascular smooth muscle cells and promotes pulmonary hypertension through changes in proliferation, apoptosis, and fibrosis[J]. Am J Physiol Lung Cell Mol Physiol, 2019, 316: L784-L797.
33 Xing J, Cao Y, Yu Y, et al. In vitro micropatterned human pluripotent stem cell test(microP-hPST)for morphometric-based teratogen screening[J]. Sci Rep, 2017, 7: 8491.
34 Galiè N, Muller K, Scalise AV, et al. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension[J]. Eur Respir J,2015, 45: 1314-1322.
35 Boucly A, O'Connell C, Savale L, et al. Tunnelled central venous line-associated infections in patients with pulmonary arterial hypertension treated with intravenous prostacyclin[J]. Presse Med, 2016, 45: 20-28.
36 White RJ, Jerjes-Sanchez C, Bohns Meyer GM, et al. Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial[J]. Am J Respir Crit Care Med, 2020, 201: 707-717.
37 Hoeper MM, McLaughlin VV, Barbera JA, et al. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study[J]. Lancet Respir Med, 2016, 4: 894-901.
38 He W, Xin X, Li Y, et al. Rod-shaped drug particles for cancer therapy: the importance of particle size and participation of caveolae pathway[J]. Part Part Syst Charact, 2017, 34: 1600371.
39 Guo J, Tardy BL, Christofferson AJ, et al. Modular assembly of superstructures from polyphenol-functionalized building blocks[J]. Nat Nanotechnol, 2016, 11: 1105-1111.
40 Li B, He W, Ye L, et al. Targeted delivery of sildenafil for inhibiting pulmonary vascular remodeling[J]. Hypertension, 2019, 73: 703-711.
41 Huang F, Jiang X, Sallam AM, et al. A nanocrystal platform based on metal-phenolic network wrapping for drug solubilization[J]. AAPS PharmSciTech, 2022, 23: 76.
42 Magar KT, Boafo GF, Zoulikha M, et al. Metal phenolic network-stabilized nanocrystals of andrographolide to alleviate macrophage-mediated inflammation invitro[J]. Chin Chem Lett, 2023, 34: 107453.
43 Bingbing Li, Chao Teng, Huiling Yu, et al. Alleviating experimental pulmonary hypertension via co-delivering FoxO1 stimulus and apoptosis activator to hyperproliferating pulmonary arteries[J]. Acta Pharmaceutica Sinica B, 2022, https://doi.org/10.1016/j.apsb.2022.12.002
44 Vonk Noordegraaf A, Groeneveldt JA, Bogaard HJ. Pulmonary hypertension [J]. Eur Respir Rev, 2016, 25(139): 4-11.
45 Chao Teng, Chenshi Lin, Feifei Huang, et al. Intracellular codelivery of anti-inflammatory drug and anti-miR 155 to treat inflammatory disease[J]. Acta Pharm Sin B, 2020, 10(8): 1521-1533.
46 Du X, Hou Y, Huang J, et al. Cytosolic delivery of the immuno-logical adjuvant poly I︰C and cytotoxic drug crystals via a carrierfree strategy significantly amplifies immune response[J]. Acta Pharm Sin B, 2021, DOI: 10.1016/j.apsb.2021.03.014.
47 Khan MS, Memon MM, Amin E, et al. Use of balloon atrial septostomy in patients with advanced pulmonary arterial hypertension: a systematic review and meta-analysis[J]. Chest, 2019, 156: 53-63.
48 Grady RM, Canter M, Shmalts A, et al. Pulmonary-to-systemic arterial shunt in children with severe pulmonary hypertension[J]. J Am Coll Cardiol, 2021, 78: 468-477.
49 Rosenzweig EB, Ankola A, Krishnan U, et al. A novel unidirectional-valved shunt approach for end-stage pulmonary arterial hypertension: early experience in adolescents and adults[J]. J Thorac Cardiovasc Surg, 2021, 161: 1438-1446.
50 Inami T, Kataoka M, Yanagisawa R, et al. Long-term outcomes after percutaneous transluminal pulmonary angioplasty for chronic thromboembolic pulmonary hypertension[J]. Circulation, 2016, 134: 2030-2032.
51 Brenot P, Jais X, Taniguchi Y, et al. French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension[J]. Eur Respir J, 2019, 53: 1802095.
52 Ogawa A, Satoh T, Fukuda T, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: results of a multicenter registry[J]. Circ Cardiovasc Qual Outcomes, 2017, 10: e004029.
53 Kim NH, Delcroix M, Jais X, et al. Chronic thromboembolic pulmonary hypertension[J]. Eur Respir J, 2019, 53: 1801915.
54 Olsson KM, Richter MJ, Kamp JC, et al. Refined risk stratification in pulmonary arterial hypertension and timing of lung transplantation[J]. Eur Respir J, 2022, 60: 2103087.
55 Moser B, Jaksch P, Taghavi S, et al. Lung transplantation for idiopathic pulmonary arterial hypertension on intraoperative and postoperatively prolonged extracorporeal membrane oxygenation provides optimally controlled reperfusion and excellent outcome[J]. Eur J Cardiothorac Surg, 2018, 53: 178-185.
56 Savale L, Le Pavec J, Mercier O, et al. Impact of high-priority allocation on lung and heart-lung transplantation for pulmonary hypertension[J]. Ann Thorac Surg, 2017, 104: 404-411.

备注/Memo

备注/Memo:
基金项目: 国家自然青年基金资助项目(81901916)
国家重点研发计划(2020YFC2008900,2020YFC2008903)
通信作者: 卞士柱, Email: bianshizhu@163.com
胡明冬, Email: huhanshandd@163.com
更新日期/Last Update: 2023-02-20